Lymphocyte subsets show different response patterns to in vivo bound natalizumab-a flow cytometric study on patients with multiple sclerosis

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Harrer, Andrea ^a   Pilz, Georg ^a   Einhaeupl, Max ^a   Oppermann, Katrin ^a   Hitzl, Wolfgang ^a   Wipfler, Peter ^a   Sellner, Johann ^a   Golaszewski, Stefan ^a   Afazel, Shahrzad ^a   Haschke Becher, Elisabeth ^a   Trinka, Eugen ^a   Kraus, Joerg ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; NATALIZUMAB; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MONITORING; DRUG PROTEIN BINDING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NATURAL KILLER T CELL; PILOT STUDY; RELAPSE; T LYMPHOCYTE; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; METABOLISM; METHODOLOGY; TIME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; FEMALE; FLOW CYTOMETRY; HUMANS; INTEGRIN ALPHA4; LYMPHOCYTE SUBSETS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TIME FACTORS;

EID: 84857432729     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031784     Document Type: Article

References (38)

1. Kraus J, Oschmann P, (2006) The impact of interferon-beta treatment on the blood-brain barrier. Drug Discov Today 11: 755-762.
2. von Andrian UH, Engelhardt B, (2003) Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 348: 68-72.
3. Eikelenboom MJ, Killestein J, Izeboud T, Kalkers NF, Baars PA, et al. (2005) Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS. J Neuroimmunol 158: 222-230.
4. Wipfler P, Oppermann K, Pilz G, Afazel S, Haschke-Becher E, et al. (2011) Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. Mult Scler 17: 16-23.
5. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356: 63-66.
6. Lutterotti A, Sospedra M, Martin R, (2008) Antigen-specific therapies in MS- Current concepts and novel approaches. J Neurol Sci 274: 18-22.
7. Wipfler P, Harrer A, Pilz G, Oppermann K, Trinka E, et al. (2011) Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options. Drug Discov Today 16: 8-21.
8. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
9. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15-23.
10. Krumbholz M, Meinl I, Kumpfel T, Hohlfeld R, Meinl E, (2008) Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71: 1350-1354.
11. Skarica M, Eckstein C, Whartenby KA, Calabresi PA, (2011) Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol 235: 70-76.
12. Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, et al. (2010) Natalizumab treatment reduces endothelial activity in MS patients. J Neuroimmunol 227: 190-194.
13. Stuve O, Cepok S, Elias B, Saleh A, Hartung HP, et al. (2005) Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 62: 1620-1623.
14. del Pilar MM, Cravens PD, Winger R, Frohman EM, Racke MK, et al. (2008) Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 65: 1596-1603.
15. Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, et al. (1988) Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 318: 301-305.
16. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, et al. (2008) The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111: 3893-3895.
17. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, et al. (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9: 438-446.
18. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, et al. (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69: 1391-1403.
19. Sorensen PS, Jensen PE, Haghikia A, Lundkvist M, Vedeler C, et al. (2011) Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler.
20. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58: 840-846.
21. Kraus J, Oschmann P, Engelhardt B, Schiel C, Hornig C, et al. (1998) Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis. Acta Neurol Scand 98: 102-109.
22. Kraus J, Engelhardt B, Kuehne BS, Laske C, Stolz E, et al. (2001) Soluble and cell surface bound adhesion molecules in blood and cerebrospinal fluid as diagnostic markers and parameters for disease activity, disease severity and treatment efficacy in patients with multiple sclerosis. J Lab Med 25: 548-56.
23. Harrer A, Wipfler P, Einhaeupl M, Pilz G, Oppermann K, et al. (2011) Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells. J Neuroimmunol 234: 148-154.
24. Niino M, Bodner C, Simard ML, Alatab S, Gano D, et al. (2006) Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 59: 748-754.
25. Foster GR, Masri SH, David R, Jones M, Datta A, et al. (2004) IFN-alpha subtypes differentially affect human T cell motility. J Immunol 173: 1663-1670.
26. Stuve O, Marra CM, Bar-Or A, Niino M, Cravens PD, et al. (2006) Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63: 1383-1387.
27. Cavers M, Afzali B, Macey M, McCarthy DA, Irshad S, et al. (2002) Differential expression of beta1 and beta2 integrins and L-selectin on CD4+ and CD8+ T lymphocytes in human blood: comparative analysis between isolated cells, whole blood samples and cryopreserved preparations. Clin Exp Immunol 127: 60-65.
28. Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, et al. (1998) A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J Neuroimmunol 86: 123-133.
29. Kastrukoff LF, Lau A, Wee R, Zecchini D, White R, et al. (2003) Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity. J Neuroimmunol 145: 103-114.
30. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, et al. (2001) Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97: 3146-3151.
31. Airas L, Saraste M, Rinta S, Elovaara I, Huang YH, et al. (2008) Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol 151: 235-243.
32. Saraste M, Irjala H, Airas L, (2007) Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 28: 121-126.
33. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, et al. (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 103: 5941-5946.
34. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M, (1999) A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 52: 1072-1074.
35. Baumann A, (2006) Early development of therapeutic biologics-pharmacokinetics. Curr Drug Metab 7: 15-21.
36. Roopenian DC, Akilesh S, (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7: 715-725.
37. Rispens T, Leeuwen A, Vennegoor A, Killestein J, Aalberse RC, et al. (2011) Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. Anal Biochem 411: 271-276.
38. Defer G, Mariotte D, Derache N, Toutirais O, Legros H, et al. (2011) CD49d expression as a promising biomarker to monitor natalizumab efficacy. J Neurol Sci.